Skip to main content

Medicinova Inc(MNOV-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

Globe Newswire - Thu Jul 21, 2022

LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of a new MN-166 (ibudilast) parenteral formulation. The newly developed MN-166 (ibudilast) formulation will provide an additional option for health care providers to administer MN-166 (ibudilast), in addition to the current oral formulation.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe